The pathophysiology and treatment of delayed cerebral ischaemia following subarachnoid haemorrhage

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 12, 2014, Pages 1343-1353

  Budohoski, Karol P ^a   Guilfoyle, Mathew ^a   Helmy, Adel ^a   Huuskonen, Terhi ^a,b   Czosnyka, Marek ^a   Kirollos, Ramez ^a   Menon, David K ^a   Pickard, John D ^a   Kirkpatrick, Peter J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; BRAIN ISCHEMIA; COMPLICATION; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; SUBARACHNOID HEMORRHAGE; VASOSPASM, INTRACRANIAL;

BRAIN; BRAIN ISCHEMIA; HUMANS; INFLAMMATION; SUBARACHNOID HEMORRHAGE; VASOSPASM, INTRACRANIAL;

EID: 84921820302     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-307711     Document Type: Review

References (214)

1. Linn FH, Rinkel GJ, Algra A, et al. Incidence of subarachnoid hemorrhage: role of region, year, and rate of computed tomography: a meta-analysis. Stroke 1996;27:625-9.
2. ACROSS. Epidemiology of aneurysmal subarachnoid hemorrhage in Australia and New Zealand: incidence and case fatality from the Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS). Stroke 2000;31:1843-50.
3. Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology 1998;50:1413-18.
4. Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: population-based study and systematic review. Neurology 2010;74:1494-501.
5. Komotar RJ, Schmidt JM, Starke RM, et al. Resuscitation and critical care of poor-grade subarachnoid hemorrhage. Neurosurgery 2009;64:397-410; discussion 410-1.
6. Hop JW, Rinkel GJ, Algra A, et al. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 1997;28:660-4.
7. Hop JW, Rinkel GJ, Algra A, et al. Quality of life in patients and partners after aneurysmal subarachnoid hemorrhage. Stroke 1998;29:798-804.
8. Rabinstein AA, Friedman JA, Weigand SD, et al. Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 2004;35:1862-6.
9. Hijdra A, Van Gijn J, Stefanko S, et al. Delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: clinicoanatomic correlations. Neurology 1986;36:329-33.
10. Rosengart AJ, Schultheiss KE, Tolentino J, et al. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke 2007;38:2315-21.
11. Vergouwen MD, de Haan RJ, Vermeulen M, et al. Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke 2010;41:e47-52.
12. Ecker A, Riemenschneider PA. Arteriographic demonstration of spasm of the intracranial arteries, with special reference to saccular arterial aneurysms. J Neurosurg 1951;8:660-7.
13. Allcock JM, Drake CG. Postoperative angiography in cases of ruptured intracranial aneurysm. J Neurosurg 1963;20:752-9.
14. Harders AG, Gilsbach JM. Time course of blood velocity changes related to vasospasm in the circle of Willis measured by transcranial Doppler ultrasound. J Neurosurg 1987;66:718-28.
15. Carrera E, Schmidt JM, Oddo M, et al. Transcranial Doppler for predicting delayed cerebral ischemia after subarachnoid hemorrhage. Neurosurgery 2009;65:316-23; discussion 323-4.
16. Crowley RW, Medel R, Dumont AS, et al. Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke 2011;42:919-23.
17. Fisher CM, Roberson GH, Ojemann RG. Cerebral vasospasm with ruptured saccular aneurysm - the clinical manifestations. Neurosurgery 1977;1:245-8.
18. Grosset DG, Straiton J, du Trevou M, et al. Prediction of symptomatic vasospasm after subarachnoid hemorrhage by rapidly increasing transcranial Doppler velocity and cerebral blood flow changes. Stroke 1992;23:674-9.
19. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1-9.
20. Claassen J, Bernardini GL, Kreiter K, et al. Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. Stroke 2001;32:2012-20.
21. Hijdra A, van Gijn J, Nagelkerke NJ, et al. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke 1988;19:1250-6.
22. Macdonald RL, Weir BK. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 1991;22:971-82.
23. Macdonald RL, Weir BK, Runzer TD, et al. Etiology of cerebral vasospasm in primates. J Neurosurg 1991;75:415-24.
24. Buckell M. Demonstration of Substances Capable of Contracting Smooth Muscle in the Haematoma Fluid from Certain Cases of Ruptured Cerebral Aneurysm. J Neurol Neurosurg Psychiatry 1964;27:198-9.
25. Toda N, Shimizu K, Ohta T. Mechanism of cerebral arterial contraction induced by blood constituents. J Neurosurg 1980;53:312-22.
26. Toda N. Mechanisms of contracting action of oxyhemoglobin in isolated monkey and dog cerebral arteries. Am J Physiol 1990;258(1 Pt 2):H57-63.
27. Macdonald RL, Weir BK, Grace MG, et al. Morphometric analysis of monkey cerebral arteries exposed in vivo to whole blood, oxyhemoglobin, methemoglobin, and bilirubin. Blood Vessels 1991;28:498-510.
28. Doczi T. The pathogenetic and prognostic significance of blood-brain barrier damage at the acute stage of aneurysmal subarachnoid haemorrhage. Clinical and experimental studies. Acta Neurochir (Wien) 1985;77:110-32.
29. Doczi T, Joo F, Adam G, et al. Blood-brain barrier damage during the acute stage of subarachnoid hemorrhage, as exemplified by a new animal model. Neurosurgery 1986;18:733-9.
30. Doczi T, Joo F, Sonkodi S, et al. Increased vulnerability of the blood-brain barrier to experimental subarachnoid hemorrhage in spontaneously hypertensive rats. Stroke 1986;17:498-501.
31. Pradilla G, Chaichana KL, Hoang S, et al. Inflammation and cerebral vasospasm after subarachnoid hemorrhage. Neurosurg Clin N Am 2010;21:365-79.
32. Fassbender K, Hodapp B, Rossol S, et al. Endothelin-1 in subarachnoid hemorrhage: An acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke 2000;31:2971-5.
33. Fassbender K, Hodapp B, Rossol S, et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry 2001;70:534-7.
34. Griffith TM, Edwards DH, Lewis MJ, et al. The nature of endothelium-derived vascular relaxant factor. Nature 1984;308:645-7.
35. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
36. Sehba FA, Schwartz AY, Chereshnev I, et al. Acute decrease in cerebral nitric oxide levels after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2000;20:604-11.
37. Khaldi A, Zauner A, Reinert M, et al. Measurement of nitric oxide and brain tissue oxygen tension in patients after severe subarachnoid hemorrhage. Neurosurgery 2001;49:33-8; discussion 38-40.
38. Kim P, Lorenz RR, Sundt TM Jr, et al. Release of endothelium-derived relaxing factor after subarachnoid hemorrhage. J Neurosurg 1989;70:108-14.
39. Pluta RM, Thompson BG, Dawson TM, et al. Loss of nitric oxide synthase immunoreactivity in cerebral vasospasm. J Neurosurg 1996;84:648-54.
40. Iuliano BA, Pluta RM, Jung C, et al. Endothelial dysfunction in a primate model of cerebral vasospasm. J Neurosurg 2004;100:287-94.
41. Hino A, Tokuyama Y, Weir B, et al. Changes in endothelial nitric oxide synthase mRNA during vasospasm after subarachnoid hemorrhage in monkeys. Neurosurgery 1996;39:562-7; discussion 567-8.
42. Jung CS, Oldfield EH, Harvey-White J, et al. Association of an endogenous inhibitor of nitric oxide synthase with cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 2007;107:945-50.
43. Nishizawa S, Yamamoto S, Yokoyama T, et al. Chronological changes of arterial diameter, cGMP, and protein kinase C in the development of vasospasm. Stroke 1995;26:1916-20; discussion 1920-1.
44. Nishizawa S, Yamamoto S, Yokoyama T, et al. Dysfunction of nitric oxide induces protein kinase C activation resulting in vasospasm after subarachnoid hemorrhage. Neurol Res 1997;19:558-62.
45. Pluta RM, Oldfield EH, Boock RJ. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg 1997;87:746-51.
46. Raabe A, Zimmermann M, Setzer M, et al. Effect of intraventricular sodium nitroprusside on cerebral hemodynamics and oxygenation in poor-grade aneurysm patients with severe, medically refractory vasospasm. Neurosurgery 2002;50:1006-13; discussion 1013-4.
47. Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther 2005;105:23-56.
48. Pluta RM, Oldfield EH, Bakhtian KD, et al. Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS ONE 2011;6:e14504.
49. Suhardja A. Mechanisms of disease: roles of nitric oxide and endothelin-1 in delayed cerebral vasospasm produced by aneurysmal subarachnoid hemorrhage. Nat Clin Pract Cardiovasc Med 2004;1:110-16; quiz 2 p following 116.
50. Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 2000;92:390-400.
51. Seifert V, Loffler BM, Zimmermann M, et al. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg 1995;82:55-62.
52. Mascia L, Fedorko L, Stewart DJ, et al. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke 2001;32:1185-90.
53. Roux S, Breu V, Giller T, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997;283:1110-18.
54. Vatter H, Zimmermann M, Tesanovic V, et al. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: inhibitory effect on endothelin(A) receptor-mediated contraction. J Neurosurg 2005;102:1101-7.
55. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011;10:618-25.
56. Macdonald RL, Higashida RT, Keller E, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke 2012;43:1463-9.
57. Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008;39:3015-21.
58. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005;103:9-17.
59. Vergouwen MD, Algra A, Rinkel GJ. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke 2012;43:2671-6.
60. Dankbaar JW, Rijsdijk M, van der Schaaf IC, et al. Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neuroradiology 2009;51:813-19.
61. Hattingen E, Blasel S, Dettmann E, et al. Perfusion-weighted MRI to evaluate cerebral autoregulation in aneurysmal subarachnoid haemorrhage. Neuroradiology 2008;50:929-38.
62. Ishii R. Regional cerebral blood flow in patients with ruptured intracranial aneurysms. J Neurosurg 1979;50:587-94.
63. Ohkuma H, Manabe H, Tanaka M, et al. Impact of cerebral microcirculatory changes on cerebral blood flow during cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 2000;31:1621-7.
64. Ohta H, Ito Z. [Cerebral infraction due to vasospasm, revealed by computed tomography (author's transl)]. Neurol Med Chir (Tokyo) 1981;21:365-72.
65. Vora YY, Suarez-Almazor M, Steinke DE, et al. Role of transcranial Doppler monitoring in the diagnosis of cerebral vasospasm after subarachnoid hemorrhage. Neurosurgery 1999;44:1237-47; discussion 1247-8.
66. Dehdashti AR, Mermillod B, Rufenacht DA, et al. Does treatment modality of intracranial ruptured aneurysms influence the incidence of cerebral vasospasm and clinical outcome? Cerebrovasc Dis 2004;17:53-60.
67. Weidauer S, Lanfermann H, Raabe A, et al. Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA study. Stroke 2007;38:1831-6.
68. Rabinstein AA, Weigand S, Atkinson JL, et al. Patterns of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 2005;36:992-7.
69. Brown RJ, Kumar A, Ilodigwe D, et al. The relationship between delayed infarcts and angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurg 2013;72:702-8.
70. Kelly PJ, Gorten RJ, Grossman RG, et al. Cerebral perfusion, vascular spasm, and outcome in patients with ruptured intracranial aneurysms. J Neurosurg 1977;47:44-9.
71. Geraud G, Tremoulet M, Guell A, et al. The prognostic value of noninvasive CBF measurement in subarachnoid hemorrhage. Stroke 1984;15:301-5.
72. Simeone FA, Trepper PJ, Brown DJ. Cerebral blood flow evaluation of prolonged experimental vasospasm. J Neurosurg 1972;37:302-11.
73. Hatazawa J, Iida H, Shimosegawa E, et al. Regional cerebral blood flow measurement with iodine-123-IMP autoradiography: normal values, reproducibility and sensitivity to hypoperfusion. J Nucl Med 1997;38:1102-8.
74. Heilbrun MP, Olesen J, Lassen NA. Regional cerebral blood flow studies in subarachnoid hemorrhage. J Neurosurg 1972;37:36-44.
75. Minhas PS, Menon DK, Smielewski P, et al. Positron emission tomographic cerebral perfusion disturbances and transcranial Doppler findings among patients with neurological deterioration after subarachnoid hemorrhage. Neurosurgery 2003;52:1017-22; discussion 1022-4.
76. Dhar R, Scalfani MT, Blackburn S, et al. Relationship between angiographic vasospasm and regional hypoperfusion in aneurysmal subarachnoid hemorrhage. Stroke 2012;43:1788-94.
77. Mir DI, Gupta A, Dunning A, et al. CT Perfusion for detection of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. AJNR Am J Neuroradiol 2013.
78. Etminan N, Vergouwen MD, Ilodigwe D, et al. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab 2011;31:1443-51.
79. Haley EC Jr, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 1993;78:537-47.
80. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. Bmj 1989;298:636-42.
81. Rinkel GJ, Feigin VL, Algra A, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2005;(1):CD000277.
82. Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988;68:505-17.
83. Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 2007;3:256-63.
84. Rabinstein AA. Secondary brain injury after aneurysmal subarachnoid haemorrhage: more than vasospasm. Lancet Neurol 2011;10:593-5.
85. Claassen J, Carhuapoma JR, Kreiter KT, et al. Global cerebral edema after subarachnoid hemorrhage: frequency, predictors, and impact on outcome. Stroke 2002;33:1225-32.
86. Hop JW, Rinkel GJ, Algra A, et al. Initial loss of consciousness and risk of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke 1999;30:2268-71.
87. Schmidt JM, Rincon F, Fernandez A, et al. Cerebral infarction associated with acute subarachnoid hemorrhage. Neurocrit Care 2007;7:10-17.
88. Wartenberg KE, Sheth SJ, Michael Schmidt J, et al. Acute ischemic injury on diffusion-weighted magnetic resonance imaging after poor grade subarachnoid hemorrhage. Neurocrit Care 2011;14:407-15.
89. Broderick JP, Brott TG, Duldner JE, et al. Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke 1994;25:1342-7.
90. Cahill J, Calvert JW, Zhang JH. Mechanisms of early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2006;26:1341-53.
91. Grote E, Hassler W. The critical first minutes after subarachnoid hemorrhage. Neurosurgery 1988;22:654-61.
92. Schubert GA, Seiz M, Hegewald AA, et al. Acute hypoperfusion immediately after subarachnoid hemorrhage: a xenon contrast-enhanced CT study. J Neurotrauma 2009;26:2225-31.
93. Schubert GA, Seiz M, Hegewald AA, et al. Hypoperfusion in the acute phase of subarachnoid hemorrhage. Acta Neurochir Suppl 2010;110:35-8.
94. Voldby B, Enevoldsen EM. Intracranial pressure changes following aneurysm rupture. Part 1: clinical and angiographic correlations. J Neurosurg 1982;56:186-96.
95. Nornes H. Cerebral arterial flow dynamics during aneurysm haemorrhage. Acta Neurochir (Wien) 1978;41:39-48.
96. Martin WR, Baker RP, Grubb RL, et al. Cerebral blood volume, blood flow, and oxygen metabolism in cerebral ischaemia and subarachnoid haemorrhage: an in-vivo study using positron emission tomography. Acta Neurochir (Wien) 1984;70:3-9.
97. Bijlenga P, Czosnyka M, Budohoski KP, et al. "Optimal cerebral perfusion pressure" in poor grade patients after subarachnoid hemorrhage. Neurocrit Care 2010;13:17-23.
98. Nornes H. The role of intracranial pressure in the arrest of hemorrhage in patients with ruptured intracranial aneurysm. J Neurosurg 1973;39:226-34.
99. Hasegawa Y, Suzuki H, Sozen T, et al. Apoptotic mechanisms for neuronal cells in early brain injury after subarachnoid hemorrhage. Acta Neurochir Suppl 2010;110:43-8.
100. Scholler K, Trinkl A, Klopotowski M, et al. Characterization of microvascular basal lamina damage and blood-brain barrier dysfunction following subarachnoid hemorrhage in rats. Brain Res 2007;1142:237-46.
101. Thal SC, Sporer S, Schmid-Elsaesser R, et al. Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome. Crit Care Med 2009;37:2228-34.
102. Hanafy KA, Morgan Stuart R, Fernandez L, et al. Cerebral inflammatory response and predictors of admission clinical grade after aneurysmal subarachnoid hemorrhage. J Clin Neurosci 2010;17:22-5.
103. Sozen T, Tsuchiyama R, Hasegawa Y, et al. Immunological Response in Early Brain Injury After SAH. Acta Neurochir Suppl 2011;110:57-61.
104. Laszlo FA, Varga C, Doczi T. Cerebral oedema after subarachnoid haemorrhage. Pathogenetic significance of vasopressin. Acta Neurochir (Wien) 1995;133:122-33.
105. Helbok R, Ko SB, Schmidt JM, et al. Global cerebral edema and brain metabolism after subarachnoid hemorrhage. Stroke 2011;42:1534-9.
106. Zetterling M, Hallberg L, Ronne-Engstrom E. Early global brain oedema in relation to clinical admission parameters and outcome in patients with aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 2010;152:1527-33; discussion 1533.
107. Friedrich B, Muller F, Feiler S, et al. Experimental subarachnoid hemorrhage causes early and long-lasting microarterial constriction and microthrombosis: an in-vivo microscopy study. J Cereb Blood Flow Metab 2012;32:447-55.
108. Udoetuk JD, Stiefel MF, Hurst RW, et al. Admission angiographic cerebral circulation time may predict subsequent angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 2007;61:1152-9; discussion 1159-61.
109. Friedrich V, Flores R, Muller A, et al. Luminal platelet aggregates in functional deficits in parenchymal vessels after subarachnoid hemorrhage. Brain Res 2010;1354:179-87.
110. Sehba FA, Mostafa G, Friedrich V Jr, et al. Acute microvascular platelet aggregation after subarachnoid hemorrhage. J Neurosurg 2005;102:1094-100.
111. Yamamoto S, Nishizawa S, Tsukada H, et al. Cerebral blood flow autoregulation following subarachnoid hemorrhage in rats: chronic vasospasm shifts the upper and lower limits of the autoregulatory range toward higher blood pressures. Brain Res 1998;782:194-201.
112. Jaeger M, Schuhmann MU, Soehle M, et al. Continuous monitoring of cerebrovascular autoregulation after subarachnoid hemorrhage by brain tissue oxygen pressure reactivity and its relation to delayed cerebral infarction. Stroke 2007;38:981-6.
113. Jaeger M, Soehle M, Schuhmann MU, et al. Clinical Significance of Impaired Cerebrovascular Autoregulation After Severe Aneurysmal Subarachnoid Hemorrhage. Stroke 2012;43:2097-101.
114. Lam JM, Smielewski P, Czosnyka M, et al. Predicting delayed ischemic deficits after aneurysmal subarachnoid hemorrhage using a transient hyperemic response test of cerebral autoregulation. Neurosurgery 2000;47:819-25; discussions 825-6.
115. Asaeda M, Sakamoto M, Kurosaki M, et al. A non-enzymatic derived arachidonyl peroxide, 8-iso-prostaglandin F2 alpha, in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage participates in the pathogenesis of delayed cerebral vasospasm. Neurosci Lett 2005;373:222-5.
116. Gaetani P, Lombardi D. Brain damage following subarachnoid hemorrhage: the imbalance between anti-oxidant systems and lipid peroxidative processes. J Neurosurg Sci 1992;36:1-10.
117. Gaetani P, Marzatico F, Rodriguez y Baena R, et al. Arachidonic acid metabolism and pathophysiologic aspects of subarachnoid hemorrhage in rats. Stroke 1990;21:328-32.
118. Gaetani P, Pasqualin A, Rodriguez y Baena R, et al. Oxidative stress in the human brain after subarachnoid hemorrhage. J Neurosurg 1998;89:748-54.
119. Hsieh YP, Lin CL, Shiue AL, et al. Correlation of F4-neuroprostanes levels in cerebrospinal fluid with outcome of aneurysmal subarachnoid hemorrhage in humans. Free Radic Biol Med 2009;47:814-24.
120. Kamezaki T, Yanaka K, Nagase S, et al. Increased levels of lipid peroxides as predictive of symptomatic vasospasm and poor outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002;97:1302-5.
121. Marzatico F, Gaetani P, Cafe C, et al. Antioxidant enzymatic activities after experimental subarachnoid hemorrhage in rats. Acta Neurol Scand 1993;87:62-6.
122. Endo H, Nito C, Kamada H, et al. Reduction in oxidative stress by superoxide dismutase overexpression attenuates acute brain injury after subarachnoid hemorrhage via activation of Akt/glycogen synthase kinase-3beta survival signaling. J Cereb Blood Flow Metab 2007;27:975-82.
123. Ayer RE, Zhang JH. Oxidative stress in subarachnoid haemorrhage: significance in acute brain injury and vasospasm. Acta Neurochir Suppl 2008;104:33-41.
124. Cahill J, Calvert JW, Solaroglu I, et al. Vasospasm and p53-induced apoptosis in an experimental model of subarachnoid hemorrhage. Stroke 2006;37:1868-74.
125. Prunell GF, Svendgaard NA, Alkass K, et al. Delayed cell death related to acute cerebral blood flow changes following subarachnoid hemorrhage in the rat brain. J Neurosurg 2005;102:1046-54.
126. Lee JY, He Y, Sagher O, et al. Activated autophagy pathway in experimental subarachnoid hemorrhage. Brain Res 2009;1287:126-35.
127. Matz PG, Fujimura M, Lewen A, et al. Increased cytochrome c-mediated DNA fragmentation and cell death in manganese-superoxide dismutase-deficient mice after exposure to subarachnoid hemolysate. Stroke 2001;32:506-15.
128. Gules I, Satoh M, Nanda A, et al. Apoptosis, blood-brain barrier, and subarachnoid hemorrhage. Acta Neurochir Suppl 2003;86:483-7.
129. Yamaura I, Tani E, Saido TC, et al. Calpain-calpastatin system of canine basilar artery in vasospasm. J Neurosurg 1993;79:537-43.
130. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2009;40:e331-9.
131. Park S, Yamaguchi M, Zhou C, et al. Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke 2004;35:2412-17.
132. Friedrich V, Flores R, Sehba FA. Cell death starts early after subarachnoid hemorrhage. Neurosci Lett 2012;512:6-11.
133. Graetz D, Nagel A, Schlenk F, et al. High ICP as trigger of proinflammatory IL-6 cytokine activation in aneurysmal subarachnoid hemorrhage. Neurol Res 2010;32:728-35.
134. Yundt KD, Grubb RL Jr, Diringer MN, et al. Autoregulatory vasodilation of parenchymal vessels is impaired during cerebral vasospasm. J Cereb Blood Flow Metab 1998;18:419-24.
135. Herz DA, Baez S, Shulman K. Pial microcirculation in subarachnoid hemorrhage. Stroke 1975;6:417-24.
136. Ohkuma H, Itoh K, Shibata S, et al. Morphological changes of intraparenchymal arterioles after experimental subarachnoid hemorrhage in dogs. Neurosurgery 1997;41:230-5; discussion 235-6.
137. Hart MN. Morphometry of brain parenchymal vessels following subarachnoid hemorrhage. Stroke 1980;11:653-5.
138. Frijns CJ, Fijnheer R, Algra A, et al. Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage: associations with cerebral ischaemic events and outcome. J Neurol Neurosurg Psychiatry 2006;77:77-83.
139. Ikeda K, Asakura H, Futami K, et al. Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage. Neurosurgery 1997;41:344-9; discussion 349-50.
140. Ohkuma H, Suzuki S, Kimura M, et al. Role of platelet function in symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 1991;22:854-9.
141. Peltonen S, Juvela S, Kaste M, et al. Hemostasis and fibrinolysis activation after subarachnoid hemorrhage. J Neurosurg 1997;87:207-14.
142. Suzuki M, Kudo A, Otawara Y, et al. Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. Neurosurgery 1999;44:487-93; discussion 493-4.
143. Hirashima Y, Nakamura S, Endo S, et al. Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage. Neurochem Res 1997;22:1249-55.
144. Stein SC, Browne KD, Chen XH, et al. Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study. Neurosurgery 2006;59:781-7; discussion 787-8.
145. Roos Y. Anti fibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group. Neurology 2000;54:77-82.
146. Roos YB, Rinkel GJ, Vermeulen M, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2000;(2):CD001245.
147. Roos YB, Rinkel GJ, Vermeulen M, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2003;(2):CD001245.
148. Vermeulen M, Lindsay KW, Murray GD, et al. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med 1984;311:432-7.
149. Tsementzis SA, Hitchcock ER, Meyer CH. Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochir (Wien) 1990;102:1-10.
150. Dorhout Mees SM, Rinkel GJ, Hop JW, et al. Antiplatelet therapy in aneurysmal subarachnoid hemorrhage: a systematic review. Stroke 2003;34:2285-9.
151. Dorhout Mees SM, van den Bergh WM, Algra A, et al. Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007;(4):CD006184.
152. Chang JC, Shook LL, Biag J, et al. Biphasic direct current shift, haemoglobin desaturation and neurovascular uncoupling in cortical spreading depression. Brain 2011;133(Pt 4):996-1012.
153. Takano T, Tian GF, Peng W, et al. Cortical spreading depression causes and coincides with tissue hypoxia. Nat Neurosci 2007;10:754-62.
154. Dreier JP, Major S, Manning A, et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain 2009;132(Pt 7):1866-81.
155. Dreier JP, Woitzik J, Fabricius M, et al. Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. Brain 2006;129(Pt 12):3224-37.
156. Woitzik J, Dreier JP, Hecht N, et al. Delayed cerebral ischemia and spreading depolarization in absence of angiographic vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2012;32:203-12.
157. Bosche B, Graf R, Ernestus RI, et al. Recurrent spreading depolarizations after subarachnoid hemorrhage decreases oxygen availability in human cerebral cortex. Ann Neurol 2010;67:607-17.
158. Rasmussen G, Hauerberg J, Waldemar G, et al. Cerebral blood flow autoregulation in experimental subarachnoid haemorrhage in rat. Acta Neurochir (Wien) 1992;119:128-33.
159. Harper AM, Deshmukh VD, Sengupta D, et al. The effect of experimental spasm on the CO2 response of cerebral bloodflow in primates. Neuroradiology 1972;3:134-6.
160. Harper AM, Glass HI. Effect of alterations in the arterial carbon dioxide tension on the blood flow through the cerebral cortex at normal and low arterial blood pressures. J Neurol Neurosurg Psychiatry 1965;28:449-52.
161. Fitch W, Ferguson GG, Sengupta D, et al. Autoregulation of cerebral blood flow during controlled hypotension in baboons. J Neurol Neurosurg Psychiatry 1976;39:1014-22.
162. Pickard JD, Matheson M, Patterson J, et al. Prediction of late ischemic complications after cerebral aneurysm surgery by the intraoperative measurement of cerebral blood flow. J Neurosurg 1980;53:305-8.
163. Budohoski KP, Czosnyka M, Smielewski P, et al. Impairment of cerebral autoregulation predicts delayed cerebral ischemia after subarachnoid hemorrhage: a prospective observational study. Stroke 2012;43:3230-7.
164. Budohoski KP, Czosnyka M, Smielewski P, et al. Cerebral autoregulation after subarachnoid hemorrhage: comparison of three methods. J Cereb Blood Flow Metab 2013;33:449-56.
165. Eide PK, Sorteberg A, Bentsen G, et al. Pressure-derived versus pressure wave amplitude-derived indices of cerebrovascular pressure reactivity in relation to early clinical state and 12-month outcome following aneurysmal subarachnoid hemorrhage. J Neurosurg 2012;116:961-71.
166. Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 2005;36:1627-32.
167. Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with statins on cerebral autoregulation in patients after aneurysmal subarachnoid hemorrhage. Neurosurg Focus 2006;21:E10.
168. Tseng MY, Hutchinson PJ, Czosnyka M, et al. Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. Stroke 2007;38:1545-50.
169. Sonobe M, Takahashi S, Otsuki T, et al. [Preventive effect on intracranial arterial vasospasm using combined ventriculo-cisternal and cisternal drainage (author's transl)]. No Shinkei Geka 1981;9:1393-7.
170. Al-Tamimi YZ, Bhargava D, Feltbower RG, et al. Lumbar drainage of cerebrospinal fluid after aneurysmal subarachnoid hemorrhage: a prospective, randomized, controlled trial (LUMAS). Stroke 2012;43:677-82.
171. Bardutzky J, Witsch J, Juttler E, et al. EARLYDRAIN- outcome after early lumbar CSF-drainage in aneurysmal subarachnoid hemorrhage: study protocol for a randomized controlled trial. Trials 2011;12:203.
172. Findlay JM, Kassell NF, Weir BK, et al. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery 1995;37:168-76; discussion 177-8.
173. Hamada J, Kai Y, Morioka M, et al. Effect on cerebral vasospasm of coil embolization followed by microcatheter intrathecal urokinase infusion into the cisterna magna: a prospective randomized study. Stroke 2003;34:2549-54.
174. Hanggi D, Eicker S, Beseoglu K, et al. A multimodal concept in patients after severe aneurysmal subarachnoid hemorrhage: results of a controlled single centre prospective randomized multimodal phase I/II trial on cerebral vasospasm. Cent Eur Neurosurg 2009;70:61-7.
175. Kanamura K, Waga S, Sakakura M, et al. Comparative study of cisternal lavage methods for the treatment of cerebral vasospasm. Cerebral Vasospasm. Proceedings of the 5th international conference; 1993:471-73.
176. Li YH, Guo K, Zi XH, et al. [Combining exchange of cerebrospinal fluid with small dose of urokinase injection for subarachnoid hemorrhage]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2005;30:217-20.
177. Kramer AH, Fletcher JJ. Locally-administered intrathecal thrombolytics following aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care 2011;14:489-99.
178. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke 2012;43:1711-37.
179. Brandt L, Andersson KE, Edvinsson L, et al. Effects of extracellular calcium and of calcium antagonists on the contractile responses of isolated human pial and mesenteric arteries. J Cereb Blood Flow Metab 1981;1:339-47.
180. Roos YB, Levi M, Carroll TA, et al. Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage. Stroke 2001;32:1860-2.
181. Liu GJ, Wang ZJ, Wang YF, et al. Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. Eur J Clin Pharmacol 2012;68:131-9.
182. Zhao J, Zhou D, Guo J, et al. Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. Neurol Med Chir (Tokyo) 2011;51:679-83.
183. Birk S, Kruuse C, Petersen KA, et al. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 2004;24:1352-8.
184. Yamaguchi-Okada M, Nishizawa S, Mizutani A, et al. Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model. Cerebrovasc Dis 2009;28:135-42.
185. Suzuki S, Sayama T, Nakamura T, et al. Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report. Cerebrovasc Dis 2011;32:89-93.
186. Senbokuya N, Kinouchi H, Kanemaru K, et al. Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial. J Neurosurg 2013;118:121-30.
187. Niu PP, Yang G, Xing YQ, et al. Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Neurol Sci 2014;336:146-51.
188. Kasuya H, Onda H, Sasahara A, et al. Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery 2005;56:895-902; discussion 895-902.
189. Barth M, Capelle HH, Weidauer S, et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke 2007;38:330-6.
190. Zwienenberg-Lee M, Hartman J, Rudisill N, et al. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke 2008;39:1759-65.
191. Chou SH, Smith EE, Badjatia N, et al. A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage. Stroke 2008;39:2891-3.
192. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke 2005;36:2024-6.
193. Vergouwen MD, Meijers JC, Geskus RB, et al. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial. J Cereb Blood Flow Metab 2009;29:1444-53.
194. McLean RM. Magnesium and its therapeutic uses: a review. Am J Med 1994;96:63-76.
195. van den Bergh WM, Algra A, van der Sprenkel JW, et al. Hypomagnesemia after aneurysmal subarachnoid hemorrhage. Neurosurgery 2003;52:276-81; discussion 281-2.
196. Dorhout Mees SM, Algra A, Vandertop WP, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet 2012;380:44-9.
197. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-7.
198. Springborg JB, Ma X, Rochat P, et al. A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol 2002;135:823-9.
199. Grasso G, Buemi M, Alafaci C, et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A 2002;99:5627-31.
200. Tseng MY, Hutchinson PJ, Richards HK, et al. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg 2009;111:171-80.
201. Suarez JI, Shannon L, Zaidat OO, et al. Effect of human albumin administration on clinical outcome and hospital cost in patients with subarachnoid hemorrhage. J Neurosurg 2004;100:585-90.
202. Siironen J, Juvela S, Varis J, et al. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial. J Neurosurg 2003;99:953-9.
203. Wurm G, Tomancok B, Nussbaumer K, et al. Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo. Clin Neurol Neurosurg 2004;106:97-103.
204. Haley EC Jr, Kassell NF, Apperson-Hansen C, et al. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg 1997;86:467-74.
205. Kassell NF, Haley EC Jr, Apperson-Hansen C, et al. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg 1996;84:221-8.
206. Lanzino G, Kassell NF. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. J Neurosurg 1999;90:1018-24.
207. Lanzino G, Kassell NF, Dorsch NW, et al. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa. J Neurosurg 1999;90:1011-17.
208. Jang YG, Ilodigwe D, Macdonald RL. Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care 2009;10:141-7.
209. Zhang S, Wang L, Liu M, et al. Tirilazad for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2010;(2):CD006778.
210. Asano T, Takakura K, Sano K, et al. Effects of a hydroxyl radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: results of a multicenter, placebo-controlled double-blind trial. J Neurosurg 1996;84:792-803.
211. Saito I, Asano T, Sano K, et al. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. Neurosurgery 1998;42:269-77; discussion 277-8.
212. Munakata A, Ohkuma H, Nakano T, et al. Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2009;64:423-8; discussion 428-9.
213. Suzuki S, Sano K, Handa H, et al. Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study. Neurol Res 1989;11:79-88.
214. Gomis P, Graftieaux JP, Sercombe R, et al. Randomized, double-blind, placebo-controlled, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg 2010;112:681-8.